Key Points
- Bristol Myers Squibb SVP Phil Holzer sold 500 shares at an average price of $67.50, generating $33,750. He retains 16,862 shares, with the sale reducing his ownership by 2.88%.
- BMS reported quarterly EPS of $2.04, beating expectations of $1.60, while revenue reached $12.97 billion and rose 5.7% year over year. The company issued fiscal 2026 EPS guidance of $6.75–$7.00.
- The company pays a quarterly dividend of $0.63, equivalent to an annualized $2.52 and a 3.7% yield. Analysts collectively rate the stock “Moderate Buy,” with an average price target of $66.06.
Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) SVP Phil Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Bristol Myers Squibb Stock Down 0.4%
Shares of NYSE BMY opened at $67.68 on Thursday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $138.25 billion, a price-to-earnings ratio of 14.91, a PEG ratio of 0.18 and a beta of 0.22. The stock has a 50 day moving average price of $61.25 and a 200 day moving average price of $59.60. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb's quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.
Bristol Myers Squibb Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. Bristol Myers Squibb's dividend payout ratio is 55.51%.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on BMY. Wells Fargo & Company set a $65.00 price target on shares of Bristol Myers Squibb and gave the company an "equal weight" rating in a report on Friday, July 31st. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an "overweight" rating on the stock. BMO Capital Markets reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Citigroup restated a "neutral" rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Finally, TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $66.06.
Read Our Latest Stock Analysis on BMY
Institutional Trading of Bristol Myers Squibb
Institutional investors have recently modified their holdings of the company. California State Teachers Retirement System raised its stake in shares of Bristol Myers Squibb by 5,484.7% during the 2nd quarter. California State Teachers Retirement System now owns 185,255,963 shares of the biopharmaceutical company's stock worth $10,674,449,000 after acquiring an additional 181,938,762 shares in the last quarter. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp grew its holdings in Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company's stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at $1,947,272,000. 76.41% of the stock is currently owned by institutional investors.
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
